Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of intensive exposure therapy for pediatric obsessive-compulsive disorder
ACTRN12616000473460Phase 2Recruiting
- Sponsor
- Dr Lara Farrell
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing D-cycloserine + intensive exposure therapy with Placebo + intensive exposure therapy (2 arms). Primary endpoints: Obsessive Compulsive Diagnostic Severity, Total obsessive-compulsive disorder severity and 1 more. Started Aug 2015; status: recruiting.
02
Drugs
d-cycloserine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on ACTRN12616000473460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000473460.